News & Updates
Filter by Specialty:
First-line serplulimab + chemo ups survival in extensive-stage SCLC
The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.
First-line serplulimab + chemo ups survival in extensive-stage SCLC
02 Dec 2022
Esophagogastric junction biopsy may be forgone after endoscopic eradication of BE
Random histological sampling from the esophagogastric junction (EGJ) appears to hold low clinical relevance in patients who have undergone successful endoscopic eradication of all visible Barrett’s esophagus (BE), given that the incidence of intestinal metaplasia at the EGJ does not pose a higher risk of disease recurrence, according to a study.
Esophagogastric junction biopsy may be forgone after endoscopic eradication of BE
02 Dec 2022
Pituitary TF–based classification improves diagnostic accuracy and prognostication of nonfunctioning PitNETs
Utility of pituitary transcription factors (TFs) improves the diagnostic accuracy and prognostication of nonfunctioning pituitary neuroendocrine tumours (NF-PitNETs), according to local data and a new diagnostic classification presented at the 5th Annual Meeting of Endocrinology, Diabetes & Metabolism Hong Kong (EDM HK).
Pituitary TF–based classification improves diagnostic accuracy and prognostication of nonfunctioning PitNETs
30 Nov 2022
Trust improves uptake of adjuvant endocrine therapy in breast cancer
Breast cancer patients with a more trustful bond with their physicians appear to be more open to taking adjuvant endocrine therapy (AET) and show lower concerns regarding the treatment, a recent study has found.